American Journal of Clinical Dermatology Impact Factor

The Journal Impact Factor is a journal-level average over a defined citation window. It can help situate American Journal of Clinical Dermatology among clinically oriented dermatology venues, but it is not a manuscript-quality score, a decision rule, or evidence that a paper will be cited at that rate.

For this journal, the useful next question is whether the manuscript gives clinicians an evidence-based therapy or patient-management insight. Springer describes its scope as critical and comprehensive reviews plus clinically focused original research in dermatology. A paper can be methodologically careful and still be poorly matched if the clinical consequence is unclear, the work is limited to an in-vitro or animal setting, or the article is principally a case report. Those are fit constraints; the JIF cannot answer them.

Two current public JCR-derived directories list a 2024 JIF of 8.8 and the current 2025 JIF of 11.4. The current figure is therefore up from 8.8 by 2.6. Treat this as limited release-to-release context, not a prediction: citation-window composition, article mix, and field citation behavior can all move a journal metric.

For a decision today, use Springer's 11.4 as the current publisher-visible figure. The official journal page does not provide a validated multi-year JIF table, so this page does not reconstruct a longer history from aggregator records. Verify any formal historical analysis in licensed Clarivate JCR.

Springer's submission guidance makes the boundary unusually clear. The journal accepts clinically focused original research and reviews, including systematic reviews, but it does not publish case reports, in-vitro studies, or animal studies. Original research should have a strong link to clinical practice and may include clinical trials, meta-analyses, or outcomes research.

Before treating the 11.4 JIF as a reason to submit, ask:

• Does the manuscript change a therapy, diagnostic, prevention, or patient-management decision in a way a clinician can use?
• Is the article type one the journal explicitly accepts, rather than a case report or preclinical study?
• Does the evidence support the practical claim without overextending beyond the study population or outcome data?
• Would a specialist journal reach the actual readers more directly if the conclusion is narrow?

In our analysis of the query-owner gap, this exact metric query was reaching a broad dermatology-journal list rather than a direct source-led answer. The missing decision context was not another ranking table; it was the distinction between a citation average and the clinical relevance an editor must evaluate. In practice, a stronger submission frames the actionable patient or therapy consequence early and keeps the conclusion inside the evidence.

Submit If

• the work offers a clinically relevant insight about therapy, prevention, diagnosis, or patient management;
• the original research has a strong, explicit connection to clinical practice;
• the manuscript is a permitted review or original-research type, with the supporting evidence readers need to assess the claim; and
• the intended audience is clinicians who need a critical, evidence-based interpretation of dermatology research.

Think Twice If

• the paper is a case report, in-vitro study, or animal study, all of which the official guidelines exclude;
• the conclusion is primarily mechanistic without a credible clinical-practice connection;
• the central result is a narrow procedure or disease-area finding that a specialist title would serve better;
• the abstract promises treatment implications that the outcomes or comparison group do not support; or
• the choice is being driven mostly by the impact factor rather than by article type and reader fit.

A clinical manuscript readiness review can help check whether the abstract, methods, outcomes, and conclusion make the strongest truthful version of the clinical contribution clear before submission.

Springer links the journal's Editorial Manager submission system from its official journal page. Verify the current editorial team directly on the live Springer page before naming anyone in a cover letter. The current submission guidance sets different word limits by article type: for example, original research is normally up to 6,000 words, substantial reviews up to 8,000 words, and systematic reviews up to 10,000 words. Confirm the live guidelines before final formatting because the manuscript categories and portal instructions can change.

The current JIF, five-year JIF, timing, publishing model, and journal identity details above were checked against Springer's official journal page on July 13, 2026. The article-type and scope boundaries come from the official submission guidelines. Two public JCR-derived records provide the limited 2024 comparison figure, but Clarivate JCR is the formal source for a licensed category rank, percentile, or longer history.

The official public profile does not provide a year-by-year JIF series. Rather than copy an unverified long trend from aggregators, this page reports the current release and one independently corroborated prior-year value only. Verify any higher-stakes reporting, promotion, funding, or institutional decision directly in Clarivate JCR.